Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.38 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11399086 | 0.82 | PLAAT3 (0.41) | MAOBKMT2ASMN1; SMN2TAAR1ALDH1A1 | |
| SCHEMBL8343080 | 0.81 | TAAR1 (0.44) | MAOBKMT2AMEN1TAAR1ALDH1A1 | |
| SCHEMBL7331602 | 0.79 | TAAR1 (0.56) | MAOBKMT2AMEN1TAAR1ALDH1A1 | |
| SCHEMBL24242076 | 0.78 | MAOB (0.44) | MAOBKMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL187684 | 0.78 | ALOX5 (0.51) | ALDH1A1LMNA | |
| SCHEMBL1444146 | 0.74 | TAAR1 (0.50) | MAOBKMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL8060407 | 0.74 | TAAR1 (0.42) | MAOBKMT2AMEN1TAAR1CASP3 | |
| SCHEMBL1519992 | 0.74 | MAPT (0.56) | KMT2AMEN1HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL8959136 | 0.74 | IDO1 (0.42) | MAOBKMT2AHPGDSMN1; SMN2TAAR1 | |
| SCHEMBL9785157 | 0.73 | HPGD (0.49) | KMT2AMEN1HPGDSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170279054-A1 | COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT COMPONENTS AND ORGANIC ELECTROLUMINESCENT DEVICES USING THE SAME | E-RAY OPTOELECTRONICS TECHNOLOGY CO., LTD. (TW) | 2017-09-28 | — | — | US | disclosed |
| EP-1021402-B1 | AROMATIC C16-C20-SUBSTITUTED TETRAHYDRO PROSTAGLANDINS USEFUL AS FP AGONISTS | UNIV DUKE (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1066254-B1 | C11 OXYMYL AND HYDROXYLAMINO PROSTAGLANDINS USEFUL AS FP AGONISTS | UNIV DUKE (US) | 2005-05-25 | — | — | EP | disclosed |
| CN-1169528-C | Prostaglandin derivatives devoid of side-effects for treatment of glaucoma | �������źͶ���Լ����˾ | 2004-10-06 | — | — | CN | disclosed |
| EP-1082299-B1 | C11 OXYMYL AND HYDROXYLAMINO PROSTAGLANDINS USEFUL AS MEDICAMENTS | UNIV DUKE (US) | 2004-06-30 | — | — | EP | disclosed |
| EP-1202999-B1 | NOVEL 2-DECARBOXY-2-PHOSPHINICO PROSTAGLANDIN F ANALOGS | PROCTER & GAMBLE (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6444840-B1 | BONE DISORDERS; VISION DEFECTS | THE PROCTER & GAMBLE CO. | 2002-09-03 | — | — | US | disclosed |
| US-6410780-B1 | BONE DISORDERS; VISION DEFECTS | THE PROCTER & GAMBLE CO. | 2002-06-25 | — | — | US | disclosed |
| EP-1202999-A1 | NOVEL 2-DECARBOXY-2-PHOSPHINICO PROSTAGLANDIN F ANALOGS | THE PROCTER & GAMBLE COMPANY (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6372730-B1 | PROSTAGLANDINS FOR VISION DEFECTS, CARDIOVASCULAR DISORDERS AND BONE DISORDERS | THE PROCTER & GAMBLE COMPANY | 2002-04-16 | — | — | US | disclosed |
| EP-1082299-A1 | C11 OXYMYL AND HYDROXYLAMINO PROSTAGLANDINS USEFUL AS MEDICAMENTS | THE PROCTER & GAMBLE COMPANY (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-2001010873-A1 | NOVEL 2-DECARBOXY-2-PHOSPHINICO PROSTAGLANDIN F ANALOGS | THE PROCTER & GAMBLE COMPANY (US) | 2001-02-15 | — | — | WO | disclosed |
| EP-1066254-A1 | C11 OXYMYL AND HYDROXYLAMINO PROSTAGLANDINS USEFUL AS FP AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2001-01-10 | — | — | EP | disclosed |
| US-6107338-A | BONE DISORDERS; GLAUCOMA | THE PROCTER & GAMBLE COMPANY (US) | 2000-08-22 | — | — | US | disclosed |
| CN-1262623-A | Prostaglandin derivatives without side effects for the treatment of glaucoma | PHARMACIA & UPJOHN AB (SE) | 2000-08-09 | — | — | CN | disclosed |
| EP-1021402-A1 | AROMATIC C16-C20-SUBSTITUTED TETRAHYDRO PROSTAGLANDINS USEFUL AS FP AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999050241-A1 | C11 OXYMYL AND HYDROXYLAMINO PROSTAGLANDINS USEFUL AS MEDICAMENTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
| WO-1999050242-A1 | C11 OXYMYL AND HYDROXYLAMINO PROSTAGLANDINS USEFUL AS FP AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
| WO-1999012896-A1 | AROMATIC C16-C20-SUBSTITUTED TETRAHYDRO PROSTAGLANDINS USEFUL AS FP AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170279054-A1 | COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT COMPONENTS AND ORGANIC ELECTROLUMINESCENT DEVICES USING THE SAME | L1CAM, C1S, F10 | MAOB 919/4885KMT2A 3322/4885MEN1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.